• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌生存率的差异由显著的预后因素所解释。

Variation in prostate cancer survival explained by significant prognostic factors.

作者信息

Krongrad A, Lai H, Lai S

机构信息

Department of Urology, and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Florida, USA.

出版信息

J Urol. 1997 Oct;158(4):1487-90.

PMID:9302148
Abstract

PURPOSE

Traditional survival analytical tools do not reveal the ability of significant prognostic factors to predict (that is, explain variation in) survival. We used survival data in patients with prostate cancer to illustrate how the association of factors with survival diverges from their ability to explain variation in survival; bladder cancer was included as a point of general comparison.

MATERIALS AND METHODS

We used the 1973 to 1990 records of the Surveillance Epidemiology and End Results program. Multivariate proportional hazards models were used to identify factors that significantly associated with survival. The proportion of variation explained by these factors was estimated with the Schemper method.

RESULTS

The dataset included 10,636 patients with prostate cancer and 1,070 with bladder cancer. Median survival was significantly longer in prostate than bladder cancer; other characteristics were similarly distributed. Age, stage and marital status were associated with survival in both cancers (p value range 0.0001 to 0.0009). The total proportion of variation explained was 7.1% and 32.1% for prostate and bladder cancer, respectively. In prostate cancer, age, stage and marital status explained 0.6, 5.5 and 0.4%, of the adjusted proportion of variation explained, respectively, and in bladder cancer, they explained 14.7, 8.9 and 0.6%, respectively.

CONCLUSIONS

Proportional hazards models identified but did not reveal the ability of significant prognostic factors to explain variations in survival. The proportion of variation explained analyses illustrate why predicting survival is so difficult, especially in prostate cancer. The prognostic factors used do not possess the ability to explain variation in survival; new prognostic factors must be identified.

摘要

目的

传统的生存分析工具无法揭示显著预后因素预测(即解释)生存情况的能力。我们使用前列腺癌患者的生存数据来说明因素与生存之间的关联如何与其解释生存差异的能力相背离;将膀胱癌纳入作为一般比较的对象。

材料与方法

我们使用了监测、流行病学和最终结果计划1973年至1990年的记录。采用多变量比例风险模型来识别与生存显著相关的因素。用施佩尔方法估计这些因素所解释的变异比例。

结果

数据集包括10636例前列腺癌患者和1070例膀胱癌患者。前列腺癌患者的中位生存期明显长于膀胱癌患者;其他特征分布相似。年龄、分期和婚姻状况在两种癌症中均与生存相关(P值范围为0.0001至0.0009)。前列腺癌和膀胱癌所解释的变异总比例分别为7.1%和32.1%。在前列腺癌中,年龄、分期和婚姻状况分别解释了调整后变异比例的0.6%、5.5%和0.4%,在膀胱癌中,它们分别解释了14.7%、8.9%和0.6%。

结论

比例风险模型识别出了显著预后因素,但未揭示其解释生存差异的能力。所解释变异比例的分析说明了预测生存为何如此困难,尤其是在前列腺癌中。所使用的预后因素不具备解释生存差异的能力;必须识别新的预后因素。

相似文献

1
Variation in prostate cancer survival explained by significant prognostic factors.前列腺癌生存率的差异由显著的预后因素所解释。
J Urol. 1997 Oct;158(4):1487-90.
2
Marriage and mortality in prostate cancer.前列腺癌患者的婚姻状况与死亡率
J Urol. 1996 Nov;156(5):1696-70.
3
Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.前列腺特异性抗原/前列腺酸性磷酸酶比值是IV期前列腺癌患者的重要预后因素。
Urology. 2007 Oct;70(4):702-5. doi: 10.1016/j.urology.2007.05.019.
4
Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.淋巴管浸润是前列腺腺癌的一个独立预后因素。
J Urol. 2005 Dec;174(6):2181-5. doi: 10.1097/01.ju.0000181215.41607.c3.
5
Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.转移性(D2期)前列腺癌患者的预后因素:来自斯堪的纳维亚前列腺癌研究组-2的经验
J Urol. 1997 Jul;158(1):164-70. doi: 10.1097/00005392-199707000-00052.
6
Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.局部前列腺癌外照射放疗后前列腺活检阳性百分比及神经周围浸润与生化结果的相关性
Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):24-9. doi: 10.1016/j.ijrobp.2004.02.031.
7
Serum interleukin 6 as a prognostic factor in patients with prostate cancer.血清白细胞介素6作为前列腺癌患者的预后因素。
Clin Cancer Res. 2000 Jul;6(7):2702-6.
8
Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.前列腺癌放射治疗会增加后续患膀胱癌和直肠癌的风险:一项基于人群的队列研究。
J Urol. 2008 Nov;180(5):2005-9; discussion 2009-10. doi: 10.1016/j.juro.2008.07.038. Epub 2008 Sep 17.
9
Marriage and mortality in bladder carcinoma.膀胱癌患者的婚姻状况与死亡率
Cancer. 2005 Sep 15;104(6):1188-94. doi: 10.1002/cncr.21295.
10
The impact of marriage on bladder cancer mortality.婚姻对膀胱癌死亡率的影响。
Urol Oncol. 2009 May-Jun;27(3):263-7. doi: 10.1016/j.urolonc.2008.04.016. Epub 2008 Jul 14.

引用本文的文献

1
Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies.经多次失败的活检后,使用磁共振成像引导区域的补充芯进行相关前列腺癌的诊断。
Magn Reson Imaging. 2013 Jul;31(6):947-52. doi: 10.1016/j.mri.2013.02.007. Epub 2013 Apr 18.
2
Associations of social networks with cancer mortality: a meta-analysis.社交网络与癌症死亡率的关联:一项荟萃分析。
Crit Rev Oncol Hematol. 2010 Aug;75(2):122-37. doi: 10.1016/j.critrevonc.2009.06.003. Epub 2009 Jul 14.
3
The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.
1.5 特斯拉和 3 特斯拉磁共振成像(MRI)在前列腺癌成像及分期中的作用:贝斯以色列女执事医疗中心(BIDMC)的方法
Cancer Biomark. 2008;4(4-5):251-62. doi: 10.3233/cbm-2008-44-507.
4
Toward a better understanding of the comparatively high prostate cancer incidence rates in Utah.为了更好地理解犹他州相对较高的前列腺癌发病率。
BMC Cancer. 2003 Apr 29;3:14. doi: 10.1186/1471-2407-3-14.
5
Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer.联合磁共振成像与光谱成像的前列腺癌分子成像方法。
J Magn Reson Imaging. 2002 Oct;16(4):451-63. doi: 10.1002/jmri.10172.